Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmony Outcomes: Albiglutide CVOT in Type 2 Diabetes
NCT02465515Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Feb 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 28
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Albiglutide with Placebo (2 arms). Primary endpoint: Time to First Occurrence of Major Adverse Cardiovascular Events (MACE). Started Jul 2015; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02465515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465515.